Trexquant Investment LP Raises Position in Royalty Pharma plc (NASDAQ:RPRX)

Trexquant Investment LP lifted its stake in Royalty Pharma plc (NASDAQ:RPRX) by 482.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 520,043 shares of the biopharmaceutical company’s stock after purchasing an additional 430,697 shares during the period. Trexquant Investment LP owned 0.09% of Royalty Pharma worth $13,266,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in shares of Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company’s stock valued at $186,846,000 after acquiring an additional 46,765 shares during the period. National Bank of Canada FI lifted its holdings in Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 371 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Royalty Pharma by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 18,539 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 733 shares during the period. Brandywine Global Investment Management LLC increased its stake in shares of Royalty Pharma by 7.8% in the fourth quarter. Brandywine Global Investment Management LLC now owns 1,958,302 shares of the biopharmaceutical company’s stock worth $49,956,000 after purchasing an additional 142,176 shares in the last quarter. Finally, Allstate Corp bought a new stake in shares of Royalty Pharma during the 4th quarter valued at $299,000. 54.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on RPRX shares. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Stock Up 0.1 %

Shares of RPRX opened at $31.17 on Wednesday. The business’s 50 day simple moving average is $32.47 and its 200-day simple moving average is $28.91. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market capitalization of $17.97 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a $0.22 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.82%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.